New rare leukaemia treatment listed on PBS: Ley


double helix (DNA)

Health Minister Sussan Ley says patients with rare chronic myeloid leukaemia and acute lymphoblastic leukaemia now have affordable access to a life-changing medicine that would normally cost up to $66,500 per year for treatment.

Minister Ley says the Government will invest $20 million over five years in listing Iclusig to provide patients with greater choice and ensure they receive the most appropriate treatment for chronic myeloid leukaemia and acute lymphoblastic leukaemia.

She says that 125 Australian patients will now pay $6.10 (concessional) or $37.70 (general) for Iclusig.

“Access to new medicines is crucial if we’re to help Australians beat life threatening diseases, which so often can rob them of their independence,” Minister Ley says.

“This $20 million investment will deliver greater affordable access for patients who would otherwise pay up to $66,500 per year for the life-saving treatment for chronic myeloid leukaemia and acute lymphoblastic leukaemia.

“This new listing of Iclusig will particularly benefit patients who are intolerant of the treatments already on the Pharmaceutical Benefits Scheme for this rare disease that is most common in adults over 50.

“In fact the Coalition Government has already listed double the number of drugs compared to Labor’s last term in office and in half the time, and that investment is only going to continue to grow.”

Minister Ley says the Coalition Government has now more-than-doubled the number of new and amended drug listings on the PBS to over 798 – worth almost $3.2 billion in total since September 2013.

She says the announcement also demonstrates the importance of the Coalition Government’s PBS Reform Package.

“Meeting community expectations that new drugs will be listed quickly also comes at a significant cost, with taxpayers expected to invest $50 billion making medicines more affordable for patients over the next five years alone,” Minister Ley says.

“Our PBS reform package ensures spending on existing medicines is as efficient as possible so we can continue to list new drugs such as these as well.”

Previous John Anich awarded PSA Life Membership
Next Pharmacists reminded to renew registration

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.